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Background: In response to antigen naive CD8+, T cells differentiate into effector cells, which express Natural killer
(NK) receptors, lose CD28 expression, and die by apoptosis. However, in smaller quantities, the cells are retained for
subsequent exposure to the same antigen. Knowledge is limited regarding whether the percentages of CD28-,
Effector memory (EMRAnull/dim), and the CD16+/CD56 + CD8+ T cells of women with low-grade cervical lesions are
altered at a systemic level.
Methods: We enrolled in this study women controls and women with Human papilloma virus infection (HPV-I)
without associated cellular neoplastic changes and with Cervical Intraepithelial Neoplastic-I (CIN-I). Flow cytometry
(FC) was performed for measurement of CD28-, memory subset, and NK-like CD8 + T cells, and IL-17, IFN-gamma,
Tumor necrosis factor (TNF)-alpha, Interleukin (IL)-10, IL-6, IL-4, and IL-2. Finally, we genotyped the HPV.
Results: The CIN-I group increased the CD8 + CD28− and CD16+/56+ T cell percentage compared with that of
HPV-I and controls (p <0.01), and CD8 + CCR7-CD45RAnull/dim (EMRAnull/dim) T cells were also increased in the CIN-I
group compared with the controls (p <0.01). These two study groups were HPV- genotyped; 49% were HPV18+,
and we did not observe differences in cytokine levels among all groups.
Conclusions: Increased levels of CD28-, EMRAnull/dim, and CD16+/CD56 + CD8+ T cells of peripheral blood in
women with CIN-I may be associated with persistent HPV infection and could exert an influence on progression to
cervical cancer.
Keywords: CD28-, CD16+, CD56+, Effector memory subsets, CD8+, Cervical cancer, CIN-IIntroduction
Invasive cervical cancer (CC) is the second most common
cancer among women worldwide, with approximately 85%
of the disease burden occurring in developing countries
[1]. There is a correlation at the international level be-
tween the prevalence of the human papillomavirus
(HPV) and the incidence of CC [2]. Have been de-
scribed two types of cervical squamous epithelial lesions:
(a) Atypical squamous cells of undetermined significance
(ASCUS), and (b) Squamous intraepithelial lesions* Correspondence: maria.pita@cusur.udg.mx
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available in this article, unless otherwise stated(SIL), which including low-grade SIL [HPV-Infection
associated with cellular changes ranging from non-
neoplastic to mild dysplastic to Cervical Intraepithelial
Neoplastic-I (CIN-I)] and high-grade SIL [CIN-II,
CIN-III, and carcinoma in situ] [3].
The primary function of cytotoxic T lymphocytes and
Natural killer (NK) cells is to detect and eliminate virus-
infected or -transformed cells [4,5]. The immune response
triggered by NK cells involves a complex interaction of
receptors, perforins, granzymes, and CD8+ effector T
cells, which recognize antigens by the T cell receptor [6].
A productive CD8(+) T-cell response to a viral infection
requires rapid division and proliferation of virus-specific
CD8(+) T cells [6]. Accumulation of CD28− T cells, par-
ticularly the CD8+ subset, is one of the most prominenttral Ltd.; licensee BioMed Central Ltd. This is an Open Access article distributed
tribution License (http://creativecommons.org/licenses/by/4.0), which permits
n in any medium, provided the original work is properly credited. The Creative
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aging. CD28, a major co-stimulatory receptor, is respon-
sible for optimal antigen-mediated T-cell activation, prolif-
eration, and survival [7]. In humans, CD56+, CD161+,
CD16+, CD94+, and CD57+ represent prototypical NK
cell markers, although they are also found in a subset
of CD8+ T cells [8] that are denominated by NK-like T
cells [9,10].
In humans, memory T-cell subsets can be phenotypic-
ally classified by CCR7 expression in combination with
that of CD45RA [11]. It was shown that the effector
CD45RA+CD28 −CD8+ T-cell subset is expanded among
peripheral blood lymphocytes in patients positive for the
Human papillomavirus (HPV+) and with CC [12]. Likewise,
cytokines represent part of the complex pattern of the im-
mune response, which can contribute to the development
of cancer, as well as to combating it [13]. In this study, we
characterized the percentage of CD8+ T cells with the
phenotype CD28–, CD16+/56+, and effector memory
subsets in the peripheral blood mononuclear cells (PBMC)
of controls and patients with a diagnosis of human papil-
lomavirus infection without neoplastic changes (HPV-I),
as well as patients with CIN-I; we genotyped HPV in both
groups. In addition, we measured plasma levels of Tumor
necrosis factor alpha (TNF-α), Interferon gamma (IFN-γ),
and Interleukin-6 (IL-6), IL-17, IL-10, IL-2, and IL-4.
Methods
Patients
A total of 79 women aged 19–60 years were enrolled in
the study: 11 women without a diagnosis of cervical
lesions (controls) by the Papanicolaou (PAP) test, 37
women with HPV-I with no associated cellular neoplastic
changes, and 31 women with a diagnosis of CIN-I. The
latter two diagnoses were confirmed by biopsy according
to the Bethesda system. The mean age of female controls
was 35 ± 13 years, the mean age of patients with HPV-I
was 32 ± 10 years, and the mean age of patients with CIN-
I was 34 ± 9 years. Women included in this study with
low-grade cervical lesions had not received treatment for
HPV infection and were not pregnant. The peripheral
blood samples were obtained at the Hospital Regional in
Ciudad Guzmán, Jalisco State, Mexico, and donors were
recruited from locations in southern Jalisco State. This
study was approved by the Ethics and Research Com-
mittees of Jalisco State Health Region 06 (number 02/
RVI/2010) and the Bioethics Committee of the Centro
Universitario del Sur, Universidad de Guadalajara (UDG),
Mexico (approval number CB/001/2010).
Reagents and monoclonal antibodies
For multiparametric Flow cytometry (FC), the following
monoclonal antibodies (mAb) were used: for identifi-
cation of memory subsets, Fluorescein isothiocyanate(FITC)-conjugated human anti-CD8 (clone OKT8),
Phycoerythrin (PE)-conjugated anti-CCR7 (clone 3D12),
allophycocyanin (APC)-conjugated anti-CD45RA (clone
HI100), and Peridinin-chlorophyll protein-Cy5.5 (PerCP-
Cy5.5)-conjugated human anti-CD28 (clone CD28.2). For
identification of NK-like CD8+ T cells (CD3+ CD8+, and
CD16+/56+), we employed PerCP-Cy5.5-conjugated
human anti-CD8a, alpha chain (clone RPA-T8), PE-
conjugated anti-CD16 (clone B73.1), PE-conjugated anti-
CD56 (clone MEM188), and FITC-conjugated anti-CD3
(clone OKT3). An isotype control was employed in each
test to adjust for background fluorescence. We performed
Fluorescence minus one (FMO) staining controls to estab-
lish the parameters for gating. All mAb were purchased
from eBiosciences (San Diego, CA, USA) and staining was
performed according to the specifications provided by the
manufacturer.
Flow cytometry
We added 100 μL of peripheral blood to each tube, then
added 10 μL of one of the antibodies as previously indi-
cated, according to the panel corresponding to CD28-,
memory subsets of CD8+ T cells and NK-like CD8+ T
cells (CD16+/CD56 + CD8 + CD3+). Cells were incubated
at room temperature in the dark for 30 min; afterward, we
lysed the red blood cells with 2 mL of lysis solution 1X
(FACS Lysing Solution, 10X; BD Biosciences, San Jose,
CA, USA) and incubated these for 15 min in the dark.
Subsequently, they were washed with Phosphate buffered
saline (PBS) solution and centrifuged this at 1,500 rpm
for 5 min. The cell pellets were suspended in 500 μL of
FACS buffer and these were then analyzed in a FACS
Calibur flow cytometer (BD Biosciences). In a first
tube, we performed a dot plot, analyzed size and com-
plexity, and identified the lymphocyte region. With this
region, we conducted an analysis of a histogram for
CD3+, and we subsequently analyzed these cells to find
(CD16+/CD56 + bright/dim) NK-like CD8+ T cells.
In a second tube, we analyzed the memory subsets
and the lack of expression of CD28 in CD8+ T cells from
the lymphocyte region. We derived an initial histogram
for CD8+ T cells, and bright cells were selected. This
selection generated a dot plot with the combination of
CCR7 and CD45RA markers [14]. Cells were denomi-
nated as follows: naive (CCR7 + CD45RAbright); Central
memory (CM, CCR7 + CD45RAnull/dim), and Effector
memory RAbright (EMRAbright, CCR7–CD45RA+), RAnull/dim
(EMRAnull/dim, CCR7–CD45RA±), and RA– (EMRAnull,
CCR7–CD45RA–). Subsequently, from the same initial
histogram for CD8+ T cells, we generated other histogram
for analysis of CD28+ and CD28–, (see Additional file 1).
For each sample, we considered the percentage of at least
20,000 events, which were acquired in a FACS Calibur
(BD Biosciences). Data were processed with the CELL
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results are reported as percentages of expression.HPV genotyping
Seeplex® HPV4A ACE screening was performed according
to the manufacturer’s recommendations (Seegene). Briefly,
DNA was extracted from cervical scrapes and amplified in
a total volume of 20 μL containing 3 μL of DNA and
17 μL of the master mixture provided by the manufac-
turer. PCR was performed on a Multigene 60 thermocy-
cler (Lanet, NJ, USA) and PCR products were stored at
−20°C prior to use. Agarose gel electrophoresis was per-
formed with 5 μL of the PCR products and 5 μL of
HPV4A ACE Marker on a 2% agarose gel containing eth-
idium bromide. Colored electrophoretic bands were read
by the naked eye and interpreted according to the Seeplex®
HPV4A ACE screening user manual.Cytometric bead analysis of Th1/Th2/Th17 profile
We used the human Th1/Th2/Th17 Cytokine Cytometric
Bead (BD Biosciences) for assessment of IL-17, IFN-γ,
TNF-α, IL-10, IL-6, IL-4, and IL-2 in plasma samples from
the control, HPV-I, and CIN-I groups. The assay was per-
formed according to the manufacturer’s instructions, the
samples were processed in a BD FACSAria I cell sorter,p













Figure 1 Percentage of CD28–CD8+ T cells of control, HPV-I, and CIN-I g
non-neoplastic lesions associated with Human papillomavirus infection (HPV-
By Analysis of variance (ANOVA) testing, we found a statistically significant dif
compared to the HPV-I and control groups (p <0.01).and data analysis was carried out by the BD FCAP Array
ver.3 software.
Statistical analysis
SPSS Software for Windows ver17 (SPSS, Inc., Chicago,
IL, USA) was employed for statistical analysis. F distribu-
tion (Analysis of variance [ANOVA]) was utilized to test
the hypothesis that the averages of various populations are
normally distributed and that the Standard deviations
(SD) of two normally distributed populations are equal. A
test was used for the case of unequal variances in multiple
comparison post hoc tests (Bonferroni); p values <0.05
were considered statistically significant.
Results
Increase in CD28–CD8+ T Cells in Women with CIN-I
Compared withNon-Neoplastic Lesions Associated
with HPV-I
It was reported that CD3 and CD28 are downmodulated
in CD8+ T cells during viral infection [15]. In this study,
we determined the percentage of CD28– CD8+ T cells
by FC in 11 female controls, in 37 patients with HPV-I,
and in 31 patients with CIN-I. We found an increase in
CD28–CD8+ T cells in the CIN-I group in comparison
with the HPV-I group (52.7 ± 5.9% and 38.9 ± 5.1%, re-
spectively; p <0.01). Likewise, we observed, in the CIN-Ip < 0.01
 < 0.01
PV-I             CIN-I
roups. Controls without cervical lesions diagnosed by Papanicolaou,
I) or Cervical intraepithelial neoplastic-I (CIN-I), both diagnosed by biopsy.
ference between the percentage of CD28–CD8+ T cells in the CIN-I group
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comparison with the control group (p <0.01) (Figure 1).
Increase of EMRAnull/dim CD8+ T cells and decrease in
naive and central memory CD8+ T cells in the CIN-I group
Antigen-experienced T cells have been divided into
CD62L + CCR7+ Central memory (CM) and CD62L–
CCR7– Effector memory cells (EMC) [16]. In this study,
we used CCR7 and CD45RA for classification of the fol-
lowing five memory subsets of CD8+ T cells: Naive
(CCR7 + CD45RAbright), CM, (CCR7 + CD45RAnull/dim);
effector memory (EM) RAbright (EMRAbright; CCR7–
CD45RA+) or terminally differentiated effector; RAnull/dim
(EMRAnull/dim, CCR7–CD45RA±), and RA– (EMRAnull,
CCR7–CD45RA–) (Figure 2). In Figure 2A, we are able to
observe that 32.9 ± 16% of cells in the control group
were naive CD8+ T, while naive CD8+ T comprised
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Figure 2 Percentages of memory subsets of CD8+ T cells in control, H
subpopulations were classified as follows: A) Naive: CCR7 + CD45RAbright; B
RAbright: EMRAbright, CCR7–CD45RA+, or terminally differentiated effector; D
CCR7–CD45RA–. By Analysis of variance (ANOVA) testing, we found a statis
EMRA null/dim CD8+ T cells in the CIN-I group compared with the control g
compared with those of the control group (p <0.01).of cells in the CIN-I group. We observed that the CIN-I
group possessed a diminished percentage of this T-cell
subset compared with controls (p <0.01). We observed a
decrease in the percentage of CM CD8+ T cells in the
HPV-I (3.1 ± 2%) and CIN-I (2.6 ± 2.1%) groups compared
with that of the control group (5.3 ± 1.8%) (p <0.01)
(Figure 2B).
Figure 2C shows that the percentage of EMRAbright
or terminally differentiated effector CD8+ T cells was
15.5 ± 6.2% in the control group, 20.1 ± 11.5% in the
HPV-I group, and 26.7 ± 13.7% in the CIN-I group. No
statistically significant difference was found among the
different study groups, although there was a trend toward
higher percentages of these cells in the CIN-I group. The
percentage of EMRAnull/dim CD8+ T cells is represented in
Figure 2D; the CIN-I group underwent a statistically
significant increase in these cells (27.1 ± 10%) as com-

















Control       HPV-I         CIN-I
PV-I         CIN-I
V-I          CIN-I
PV-I, and CIN-I groups. CCR7+ and CD45RA +memory
) Central memory: CM CCR7 + CD45RA null/dim; C) Effector memory
) RAnull/dim: EMRAnull/dim CCR7–CD45RA±, and E) RA– : EMRAnull
tically significant difference between the percentages of naive, CM, and
roup (p <0.01). CM CD8+ T cells were diminished in the HPV-I group
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in the control group, 28.9 ± 12.7% in the HPV-I group,
while this was 25.5 ± 15.1% in the CIN-I group (Figure 2E).
We did not observe statistically significant differences
among these groups.
Patients with CIN-I have an increased percentage of NK-like
CD8+ T cells compared with controls and patients with
HPV-I
NK cells are classified into two subsets: the
CD56brightCD16– subset, which is associated with im-
munoregulation, and the CD56dimCD16+ subset, which is
associated with cytotoxicity. In this study, we identified
two simultaneous markers, CD16+ and CD56+, for NK-
like CD8+ T cells of controls and the HPV-I or CIN-I
groups. We observed NK-like CD8+ T cells in 4 ± 1.7% of
controls, 4.2 ± 2% in the HPV-I group, and 6.7 ± 3.9% in
the CIN-I group. There was a significant difference in the
percentage of these cells in the CIN-I group as compared
with the control and HPV-I groups (p <0.01) (Figure 3).
The majority of women with cervical preneoplastic
lesions were HPV18+
HPV16 and HPV18 are high-risk HPV associated with
around 70% of invasive carcinomas [17]. Of 68 women















Figure 3 Percentage of NK-like CD8+ T cells in control, HPV-I, and CIN
and CD16+/56 + dim/bright. By Analysis of variance (ANOVA) testing, we foun
compared with the HPV-I and control groups (p <0.01).were HPV6+/11+/18+, 3% were HPV18+/16+, and 4%
were HPV-negative, while 34% of samples were not ge-
notyped (Table 1).
There is no imbalance in the cytokine profile in patients
with low-grade cervical lesions
We assessed the presence of Th1-like cytokines IL-2,
TNF-α, and IFN-γ, and Th2-like cytokines IL-4, IL-6,
IL-10, and IL-17 in serum from the different groups, iden-
tifying cytokines that were detected in 80% or more of the
samples measured and whose levels had a variation coeffi-
cient of <30%. In general, we found low concentrations of
these cytokines in all groups, and we did not observe dif-
ferences among the control, HPV-I, and CIN-I groups
(Table 2).
Discussion
In this study, we analyzed the different subset cells
employing isotype controls in each sample; in addition,
we utilized FMO controls in some controls because,
among other reasons, isotype controls by themselves not
account for fluorescence spillover from other channels.
In our study, we observed that in the CIN-I group,
CD28-CD8+ T cells were increased (Figure 1). It is note-
worthy that CD8+ suppressor and effector T cells are
also CD28-, while not all senescent CD8+ T cells arePV-I               CIN-I
p < 0.01
p < 0.01
-I groups. To identify these cells, we used the markers CD3+, CD8+
d an increase of Natural killer (NK)-like CD8+ T cells in the CIN-I group
Table 1 HPV genotypes in patients with low-grade cervical lesions
Number of patients Diagnosis Age HPV Infection Patient’s number Diagnosis Age HPV infection
Low risk High risk Low risk High risk
1 HPV-I 29 18 35 HPV-I 48 nd
2 HPV-I 34 nd 36 HPV-I 53 nd
3 HPV-I 23 nd 37 HPV-I 44 nd
4 HPV-I 24 6, 11 18 38 CIN-I 29 18
5 HPV-I 35 18 39 CIN-I 25 18
6 HPV-I 29 18 40 CIN-I 29 18
7 HPV-I 24 18 41 CIN-I 26 18
8 HPV-I 22 18 42 CIN-I 40 nd
9 HPV-I 32 18 43 CIN-I 35 18
10 HPV-I 21 18 44 CIN-I 27 18
11 HPV-I 23 18 45 CIN-I 24 18
12 HPV-I 35 18 46 CIN-I 25 6, 11 18
13 HPV-I 39 18 47 CIN-I 26 nd
14 HPV-I 34 18 48 CIN-I 22 nd
15 HPV-I 26 16,18 49 CIN-I 27 6, 11 18
16 HPV-I 23 18 50 CIN-I 29 nd
17 HPV-I 38 nd 51 CIN-I 37 6, 11 18
18 HPV-I 27 nd 52 CIN-I 35 18
19 HPV-I 34 18 53 CIN-I 31 18
20 HPV-I 26 nd 54 CIN-I 31 18
21 HPV-I 28 18 55 CIN-I 39 18
22 HPV-I 40 18 56 CIN-I 21 Negative
23 HPV-I 24 18 57 CIN-I 28 18
24 HPV-I 25 6, 11 18 58 CIN-I 35 nd
25 HPV-I 19 6, 11 18 59 CIN-I 40 nd
26 HPV-I 36 18 60 CIN-I 38 nd
27 HPV-I 20 nd 61 CIN-I 33 Nd
28 HPV-I 21 nd 62 CIN-I 41 Nd
29 HPV-I 24 nd 63 CIN-I 41 16,18
30 HPV-I 45 18 64 CIN-I 55 Negative
31 HPV-I 44 18 65 CIN-I 45 18
32 HPV-I 44 nd 66 CIN-I 43 18
33 HPV-I 45 Negative 67 CIN-I 55 6, 1.1 18
34 HPV-I 60 nd 68 CIN-I 41 Nd
HPV = Human papillomavirus; nd = not determined.
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CD28- EM T cells, which accumulate in a variety of
diseases, as well as with increasing age, are associated
with immunological dysfunction and reduced responses to
vaccination [14,18,19], although senescent T cells in vitro
were recently characterized as having the phenotype
CD28+ CD57+ [20]. It was also shown thatthe absence of
CD28 and the presence of CD57 and KLRG1 (Killer-cell
lectin-like receptor G1) are cell-surface markers ofsenescent T-lymphocytes in humans. These cells can
secrete cytokines but have poor proliferative capacity,
and CD57+ KLRG1+ cells do not express CD27, CD28,
and CCR7, indicating that they are terminally differenti-
ated effector cells [21].
Our results suggest that in women with a diagnosis of
HPV-I (HPV infection without neoplastic cellular
changes) and CIN-I, there is an increase in CD28-CD8+ T
cells that may be related with systemic immunosuppression,
Table 2 Th1/Th2/Th17 profiles in control, HPV-I, and CIN-I
groups
Cytokine Controls HPV-I CIN-I
IL-17 13.73 ± 3.24 13.72 ± 1.81 13.56 ± 1.75
IFN-gamma 8.03 ± 1.13 8.08 ± 1.03 8.18 ± 0.93
TNF-alpha 7.52 ± 0.65 7.46 ± 0.60 7.32 ± 0.65
IL-10 6.59 ± 0.46 6.28 ± 0.50 6.80 ± 0.48
IL-6 8.70 ± 0.55 8.46 ± 0.78 8.76 ± 1.64
IL-4 8.22 ± 0.57 7.97 ± 0.54 7.96 ± 0.72
IL-2 9.18 ± 0.87 8.98 ± 1.12 9.00 ± 0.58
Cytokine plasma levels (mean ± Standard deviation) in pg/mL. Controls aged
35 ± 13 years; HPV-I, 32 ± 10 years, and CIN-I, 34 ± 9 years, who were positive
or negative for any HPV.
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promote cell activation [22,23]. This may indicate that in
women with low-grade lesions and with alterations in the
cervical epithelium due to HPV infection, the loss of
CD28 can be promoted. Along the same lines, prior stud-
ies have reported dysregulated expression of the CD28
molecule in peripheral blood T cells of patients with
advanced Cervical cancer (CC), indicating an alteration
in the systemic immune response [23]. This is import-
ant because our study shows that the deregulation of
CD28 occurs not only at the later stages of CC, but
also at its earliest stages (CIN-I), and this finding may
aid in explaining the mechanisms underlying the anti-
tumor immune response and immunoevasion. It would
be interesting to study whether patients who later reversed
their CIN-I recovered expression of CD28 in CD8+ T
cells, because an increase of CD28-CD8+ T cells was asso-
ciated with various diseases, and with chronic immune ac-
tivation such as cancer, chronic intracellular infections,
and autoimmune diseases [24], and because these cells are
nearly constantly present and functional in human tu-
mors, with the ability of to inhibit both T-cell proliferation
and cytotoxicity [25,26].
According to the model of naive-cell branched differen-
tiation, the first two daughter T cells display phenotypical
and functional indicators of being destined toward effector
and memory lineages [27]. Thus, in response to antigen
naive CD8+, T cells differentiate, activate, and expand into
effector cells, which express NK receptors, lose expression
of CD28, and die by apoptosis [28]. In our study, we ob-
served a significant decrease in naive CD8+ T cells in
the CIN-I group in comparison with the control group
(Figure 2A). In contrast, no significant differences were
observed in peripheral-blood naive CD8+ T-cell counts
between healthy donors and patients with adenocarcin-
oma of the lung [29]. Protection against intracellular
pathogens or tumor antigens requires T cell-mediated
responses, and it has become evident that protection
against disease is linked with Central memory (CM)-typeT cells [30]. In this regard, we observed a decrease of CM
cells in the HPV-I and CIN-I groups (Figure 2B). Add-
itionally, we observed that the percentage of EMRAbright
or terminally differentiated effector CD8+ T-cell subsets
had a tendency to increase in the CIN-I group rela-
tive to controls and to the HPV-I group (Figure 2C).
Similarly been shown that no differences existed in
the percentages of effector (CD45RA + CD45RO-
CD27-CD28-) CD8+ T subsets in peripheral blood
between healthy donors and patients with adenocar-
cinoma of the lung [29].
Notably, once the naive CD8+ T cell recognizes the
antigen, a smaller quantity the naive cells is retained for
subsequent exposure to the same antigen [31]. Whereas
CD45RA expression may better define senescence and
CD8+ effector memory T cells that re-express CD45RA
increase considerably in older humans [32]. We found
that EMRAnull/dim population is increased in the CIN-I
group, which could indicate a high degree of differenti-
ation and also represent “aged” CD8 T cells in this group
(Figure 2D). We previously reported that there an age-
associated increase of the Effector memory (EM), par-
ticularly the CD45RAnull/dim phenotype, in both CMV
(cytomegalovirus) pp65 pentamer-positive and negative
CD8+ T cells of healthy subjects [33]. Also, we consider
that these cells could be related with chronic antigenic
activation or persistent infection.
In addition, we observed that NK-like CD8+ T cells were
increased in patients with CIN-I relative to controls and
HPV-I groups (Figure 3). This suggests that some cells
with the CD28– CD8+ phenotype could simultaneously
be CD16+/56+, because it has been demonstrated that
CD28– T cells have enhanced cytotoxicity [34], while sim-
ultaneously performing suppressive functions [35]. These
immunologic alterations were implicated in high-grade
squamous intraepithelial lesions and persistent HPV infec-
tion [36], and we observed that the majority of women
with cervical preneoplastic lesions were HPV18 + .
We looked at whether there was systemic dysregulation
of Th1, Th2, and Th17 cytokines in women diagnosed
with HPV-I and CIN-I. Our results indicated that these
cytokine levels were similar in all of the study groups. This
is consistent with prior research that found no correlation
between carcinogenic or non-carcinogenic HPV DNA and
cytokine levels in women with HPV detected in cervix
[37]. However, changes in cytokine secretion or deregu-
lation may occur in more advanced stages of neoplastic
change or CC; a shift toward the Th2 cytokine profile
has been observed in patients with high-grade lesions or
CC [38,39].
Conclusion
Phenotypic changes in CD8 + T cells in the peripheral
blood of patients with low-grade cervical lesions may
Pita-Lopez et al. Cancer Cell International 2014, 14:97 Page 8 of 9
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neoplastic epithelial cells. Thus, the high percentages
of CD28-, EMRAnull/dim, and NK-like CD8 + T cells
could indicate the possibility of the development of
CC.
Consent
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for the publication of this report and any accompanying
images.
Additional file
Additional file 1: Dot plots and histograms representating control,
HPV-I and CIN-I groups. Analysis of CD28‒CD8+ T cells (A). Analysis of
memory subsets according to differential expression of CCR7 and
CD45RA (B). NK-like CD8+ T cells (CD16+/CD56+bright/dim CD3+) (C).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MLP-L: Conceived of and designed the study, participated in the acquisition,
analysis and interpretation of data coordination, and drafted the manuscript.
PCO-L: Performed and analyzed some of the flow cytometry of cells and all
cytokines and participated in discussion of the results and in the writing of
the manuscript. MN-M: Performed and analyzed HPV genotyping. FS-T:
Performed the statistical analysis. OP-Z: Participated in discussion of the results
and in the corrected writing of the manuscript. All authors read and approved
the final manuscript.
Acknowledgments
This study was supported by grants from PROMEP/103.5/08 2918; Sector
Funds in Health CONACyT-México no. 87993, and from the Coordination of
Research and Postgraduate Studies, Centro Universitario del Sur, Universidad
de Guadalajara CIP/390/08 (to MLP-L).
We are grateful to L. García del Ángel, M.D., Coordinator of Reproductive
Health, Health Region 06 of Jalisco and to O. Martínez-Martínez, M.D., Head
of the Dysplasia Clinic of the Hospital Regional of Ciudad Guzman, Jalisco for
the use of the facilities for obtaining samples from the patients included in
this study.
Author details
1Laboratorio de Biología Molecular e Inmunología, Centro Universitario del
Sur, Universidad de Guadalajara, Av. Enrique Arreola Silva No. 883, 49000. Cd
Guzmán, Jalisco, México. 2División de Inmunología, Centro de Investigación
Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada
No. 800, 44340 Guadalajara, Jalisco, México. 3Departamento de Ciencias
Exactas Tecnologías y Metodologías, Centro Universitario del Sur, Universidad
de Guadalajara, Av. Enrique Arreola Silva No. 883, 49000 Ciudad Guzman,
Jalisco, México. 4Direction of Chronic Infections and Cancer, Research Center
in Infection Diseases, National Institute of Public Health Av. Universidad No.
655, Cerrada los Pinos y Caminera, Col. Santa María Ahuacatitlán, 62100
Cuernavaca, Morelos, Mexico.
Received: 19 August 2014 Accepted: 11 September 2014
References
1. White HL, Mulambia C, Sinkala M, Mwanahamuntu MH, Parham GP,
Moneyham L, Grimley DM, Chamot E: ‘Worse than HIV’ or ‘not as serious
as other diseases’? Conceptualization of cervical cancer among newly
screened women in Zambia. Soc Sci Med 2012, 74:1486–1493.2. Maucort-Boulch D, Franceschi S, Plummer M: International correlation
between human papillomavirus prevalence and cervical cancer
incidence. Cancer Epidemiol Biomarkers Prev 2008, 17:717–720.
3. Broso PR, Buffetti G: [The papanicolaou classification in the Bethesda
system (National Cancer Institute, Bethesda, Maryland)]. Minerva Ginecol
1993, 45:557–563.
4. Barry M, Bleackley RC: Cytotoxic T lymphocytes: all roads lead to death.
Nat Rev Immunol 2002, 2:401–409.
5. Russell JH, Ley TJ: Lymphocyte-mediated cytotoxicity. Annu Rev Immunol
2002, 20:323–370.
6. Seedhom MO, Jellison ER, Daniels KA, Welsh RM: High frequencies of
virus-specific CD8+ T-cell precursors. J Virol 2009, 83:12907–12916.
7. Weng NP, Akbar AN, Goronzy J: CD28(−) T cells: their role in the age-
associated decline of immune function. Trends Immunol 2009, 30:306–312.
8. Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, Peña J, Solana R:
Increased expression of NK cell markers on T lymphocytes in aging and
chronic activation of the immune system reflects the accumulation of
effector/senescent T cells. Mech Ageing Dev 2000, 121:77–88.
9. Peralbo E, Alonso C, Solana R: Invariant NKT and NKT-like lymphocytes:
two different T cell subsets that are differentially affected by ageing. Exp
Gerontol 2007, 42:703–708.
10. Vallejo AN, Hamel DL Jr, Mueller RG, Ives DG, Michel JJ, Boudreau RM,
Newman AB: NK-like T cells and plasma cytokines, but not anti-viral
serology, define immune fingerprints of resilience and mild disability in
exceptional aging. PLoS One 2011, 6:e26558.
11. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of
memory T lymphocytes with distinct homing potentials and effector
functions. Nature 1999, 401:708–712.
12. Pilch H, Hoehn H, Schmidt M, Steiner E, Tanner B, Seufert R, Maeurer M:
CD8 + CD45RA + CD27-CD28-T-cell subset in PBL of cervical cancer
patients representing CD8 + T-cells being able to recognize cervical
cancer associated antigens provided by HPV 16 E7. Zentralbl Gynakol
2002, 124:406–412.
13. Alshaker HA, Matalka KZ: IFN-gamma, IL-17 and TGF-beta involvement in
shaping the tumor microenvironment: the significance of modulating such
cytokines in treating malignant solid tumors. Cancer Cell Int 2011, 11:33.
14. Weinberger B, Welzl K, Herndler-Brandstetter D, Parson W, Grubeck-Loebenstein
B: CD28(−)CD8(+) T cells do not contain unique clonotypes and are therefore
dispensable. Immunol Lett 2009, 127:27–32.
15. Trimble LA, Kam LW, Friedman RS, Xu Z, Lieberman J: CD3zeta and CD28 down-
modulation on CD8 T cells during viral infection. Blood 2000, 96:1021–1029.
16. Unsoeld H, Pircher H: Complex memory T-cell phenotypes revealed by
coexpression of CD62L and CCR7. J Virol 2005, 79:4510–4513.
17. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B,
Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera
N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu
E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A,
Suarez GA, Lombardi LE, Banjo A, et al: Human papillomavirus genotype
attribution in invasive cervical cancer: a retrospective cross-sectional
worldwide study. Lancet Oncol 2010, 11:1048–1056.
18. Nagata T, Koide Y: Induction of specific CD8 T cells against intracellular
bacteria by CD8 T-cell-oriented immunization approaches. J Biomed
Biotechnol 2010, 2010:764542.
19. Dolfi DV, Duttagupta PA, Boesteanu AC, Mueller YM, Oliai CH, Borowski AB,
Katsikis PD: Dendritic cells and CD28 costimulation are required to
sustain virus-specific CD8+ T cell responses during the effector phase
in vivo. J Immunol 2011, 186:4599–4608.
20. Onyema OO, Njemini R, Bautmans I, Renmans W, De WM, Mets T: Cellular
aging and senescence characteristics of human T-lymphocytes.
Biogerontology 2012, 13:169–181.
21. Ibegbu CC, Xu YX, Harris W, Maggio D, Miller JD, Kourtis AP: Expression of
killer cell lectin-like receptor G1 on antigen-specific human CD8+ T
lymphocytes during active, latent, and resolved infection and its relation
with CD57. J Immunol 2005, 174:6088–6094.
22. Boesteanu AC, Katsikis PD: Memory T cells need CD28 costimulation to
remember. Semin Immunol 2009, 21:69–77.
23. Kosmaczewska A, Bocko D, Ciszak L, Wlodarska-Polinska I, Kornafel J, Szteblich A,
Masternak A, Frydecka I: Dysregulated expression of both the costimulatory
CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical
cancer patients suggests systemic immunosuppression related to disease
progression. Pathol Oncol Res 2012, 18:479–489.
Pita-Lopez et al. Cancer Cell International 2014, 14:97 Page 9 of 9
http://www.cancerci.com/content/14/1/9724. Strioga M, Pasukoniene V, Characiejus D: CD8+ CD28- and CD8+ CD57+ T
cells and their role in health and disease. Immunology 2011, 134:17–32.
25. Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P,
Villaggio B, Ferrera A, Kunkl A, Rizzi M, Ferrera F, Balestra P, Ghio M, Contini
P, Setti M, Olive D, Azzarone B, Carmignani G, Ravetti JL, Torre G, Indiveri F:
CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and
cytotoxic functions infiltrate human cancers. J Immunol 2007,
179:4323–4334.
26. Tsukishiro T, Donnenberg AD, Whiteside TL: Rapid turnover of the CD8(+)
CD28(−) T-cell subset of effector cells in the circulation of patients with
head and neck cancer. Cancer Immunol Immunother 2003, 52:599–607.
27. Chang JT, Palanivel VR, Kinjyo I, Schambach F, Intlekofer AM, Banerjee A,
Longworth SA, Vinup KE, Mrass P, Oliaro J, Killeen N, Orange JS, Russell SM,
Weninger W, Reiner SL: Asymmetric T lymphocyte division in the
initiation of adaptive immune responses. Science 2007, 315:1687–1691.
28. Kaech SM, Wherry EJ, Ahmed R: Effector and memory T-cell differentiation:
implications for vaccine development. Nat Rev Immunol 2002, 2:251–262.
29. Prado-García H, Aguilar-Cázares D, Flores-Vergara H, Mandoki JJ, López-González
JS: Effector, memory and naive CD8+ T cells in peripheral blood and pleural
effusion from lung adenocarcinoma patients. Lung Cancer 2005, 47:361–371.
30. Zanetti M, Franchini G: T cell memory and protective immunity by
vaccination: is more better? Trends Immunol 2006, 27:511–517.
31. Arosa FA: CD8+CD28- T cells: certainties and uncertainties of a prevalent
human T-cell subset. Immunol Cell Biol 2002, 80:1–13.
32. Griffiths SJ, Riddell NE, Masters J, Libri V, Henson SM, Wertheimer A, Wallace
D, Sims S, Rivino L, Larbi A, Kemeny DM, Nikolich-Zugich J, Kern F,
Klenerman P, Emery VC, Akbar AN: Age-associated increase of low-avidity
cytomegalovirus-specific CD8+ T cells that re-express CD45RA. J Immunol
2013, 190:5363–5372.
33. Pita-López ML, Gayoso I, DelaRosa O, Casado JG, Alonso C, Muñoz-Gomariz
E, Tarazona R, Solana R: Effect of ageing on CMV-specific CD8 T cells from
CMV seropositive healthy donors. Immun Ageing 2009, 6:11.
34. Azuma M, Cayabyab M, Phillips JH, Lanier LL: Requirements for CD28-
dependent T cell-mediated cytotoxicity. J Immunol 1993, 150:2091–2101.
35. Ciubotariu R, Colovai AI, Pennesi G, Liu Z, Smith D, Berlocco P, Cortesini R,
Suciu-Foca N: Specific suppression of human CD4+ Th cell responses to
pig MHC antigens by CD8+. J Immunol 1998, 161:5193–5202.
36. Goncalves MA, Soares EG, Donadi EA: The influence of human
papillomavirus type and HIV status on the lymphomononuclear cell
profile in patients with cervical intraepithelial lesions of different
severity. Infect Agent Cancer 2009, 4:11.
37. Mbulaiteye SM, Kemp T, Gage JC, Ajenifuja KO, Kiruthu C, Wentzensen NA,
Adepiti C, Wacholder S, Burk RD, Schiffman M, Pinto L: Plasma cytokine
levels and human papillomavirus infection at the cervix in rural Nigerian
women. Cytokine 2013, 64:146–151.
38. Sharma A, Rajappa M, Satyam A, Sharma M: Cytokines (TH1 and TH2) in
patients with advanced cervical cancer undergoing neoadjuvant
chemoradiation: correlation with treatment response. Int J Gynecol Cancer
2009, 19:1269–1275.
39. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ,
Helmerhorst TJ: A shift to a peripheral Th2-type cytokine pattern during
the carcinogenesis of cervical cancer becomes manifest in CIN III lesions.
J Clin Pathol 2005, 58:1096–1100.
doi:10.1186/s12935-014-0097-5
Cite this article as: Pita-Lopez et al.: CD28-, CD45RAnull/dim and natural
killer-like CD8+ T cells are increased in peripheral blood of women with
low-grade cervical lesions. Cancer Cell International 2014 14:97.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
